Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

Share Price is delayed by 15 minutes
Get Live Data
31.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 2.00 (6.667%)
Market Cap: £56.06m
IKA Live PriceLast checked at - London Stock Exchange

Intraday Ilika Plc Share Chart

Goliath P1 Cells Validated by Customer Testing

1 May 2025 07:00

RNS Number : 8702G
Ilika plc
01 May 2025
Β 

Ilika plc

("Ilika", the "Group", or the "Company")

Β 

Goliath P1 Cells Validated by Customer Testing

Β 

Ilika (AIM: IKA), an independent global expert in solid-state battery technology, announces that it has received confirmation from OEM and Tier 1 testing partners that its P1 Goliath prototypes perform to specification.

Β 

Further to its RNS of May 2024 announcing commencement of testing of P1 prototype cells on behalf of, and subsequently by, commercial partners, Ilika confirms that the suite of tests including cell formation protocol, measurement of energy capacity, charge rate, power delivery capability and accelerated cyclability have confirmed the specification of its P1 cells. Furthermore, the tests demonstrated good reproducibility across the batch and delivered the expected electrochemical signature.

Β 

The tests were carried out under commercial agreements with confidentiality provisions designed to protect proprietary duty cycle protocols owned by the OEMs and Tier 1 companies. The test protocols used are representative of those used to evaluate batteries for electric vehicles and, while the protocols vary from one partner to another, the results have been consistent, and they are globally relevant.

Β 

The Head of Battery Development at an UK-based electrification Tier 1 supplying global OEMs, stated, "We can confirm that we have completed testing of Ilika's P1 prototypes and they perform to specification, putting them in the cohort of leading solid-state batteries we have tested. We look forward to evaluating further prototypes as Ilika progresses through its roadmap."

Β 

Graeme Purdy, Ilika CEO, stated, "Customer validation of our Goliath roadmap is of primary importance to us to ensure that we are progressing towards a minimum viable product that meets or exceeds customer expectations. Clearly, this set of validations increases our confidence in the attractiveness of our roadmap. We will continue to engage with a portfolio of potential manufacturing partners to minimise commercialisation risk."

Β 

In parallel with the validation programmes carried out on its P1s, Ilika has continued to develop its batteries as outlined in its 2024 annual report. In October 2024, Ilika announced compelling safety test data validated by the Faraday Institution's Safebatt programme. Ilika is currently conducting in-house testing of larger 10Ah cells associated with its materials design freeze before releasing its 10Ah (P1.5) prototypes in H2 CY25. Ilika's near-term roadmap extends through to 50Ah minimum viable product (MVP), with the first release expected at the end CY25. Ilika's Goliath MVP, or P2 prototypes, will underpin licensing opportunities.

Β 

ENDS

Β 

--

Enquiries:

Β 

Ilika Plc Graeme Purdy, Chief Executive

Jason Stewart, Chief Financial Officer

Β 

www.ilika.com

Via FTI Consulting

Β 

Cavendish Capital Markets Limited (Nomad and Broker) Peter Lynch

Neil McDonald

Β 

+44 (0)131 220 9772

+44 (0)131 220 9771

Β 

FTI Consulting (Comms Advisors)

Ben Brewerton

Elizabeth Adams

Dwight Burden

ilika@fticonsulting.com

Β 

Β 

About Ilika plcΒ -Β https://www.ilika.com

Β 

Ilika is a global expert in the development of solid state battery technology for electric vehicles, medical devices and consumer appliances. The Company's pioneering next-generation technologies aim to provide scalable, affordable alternatives to conventional batteries, to industries which need to incorporate a smaller, lighter, and safer power source in their products.

Β 

The Company has two product lines. Its Stereax batteries are designed for powering miniature medical implants, industrial wireless sensors and Internet of Things (IoT) applications and the Goliath large format batteries designed for EV cars and cordless appliances.

Β 

Through its licensing business model, Ilika supplies its IP portfolio to both OEMs and manufacturing partners in exchange for a license fee and future royalties.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCFBLFXEZLZBBF
Date   Source Headline
17th Nov 20224:40 pmRNSSecond Price Monitoring Extn
17th Nov 20224:35 pmRNSPrice Monitoring Extension
17th Nov 20229:05 amRNSSecond Price Monitoring Extn
17th Nov 20229:00 amRNSPrice Monitoring Extension
17th Nov 20227:01 amRNSAppointment of Chief Financial Officer
17th Nov 20227:00 amRNSTrading Update, Notice of Results & Presentations
22nd Sep 202212:45 pmRNSExercise of Options, PDMR Shareholding and TVR
20th Sep 20224:47 pmRNSResult of AGM
7th Sep 202210:00 amRNSGoliath Scale-up Update
18th Aug 20227:00 amRNSPosting of Annual Report and Notice of AGM
1st Aug 20229:05 amRNSSecond Price Monitoring Extn
1st Aug 20229:00 amRNSPrice Monitoring Extension
25th Jul 20223:30 pmRNSHolding(s) in Company
20th Jul 20222:05 pmRNSSecond Price Monitoring Extn
20th Jul 20222:00 pmRNSPrice Monitoring Extension
14th Jul 20227:00 amRNSExercise of Options and Total Voting Rights
13th Jul 20224:41 pmRNSSecond Price Monitoring Extn
13th Jul 20224:36 pmRNSPrice Monitoring Extension
13th Jul 20227:00 amRNSFinal Results
20th Jun 20227:00 amRNSGoliath Scale-up Update
11th May 20227:00 amRNSTrading Update & Notice of Results
4th May 20227:00 amRNSGoliath Scale-up Update
21st Mar 202211:45 amRNSDirector/PDMR Shareholding
15th Mar 202212:34 pmRNSDirector/PDMR Shareholding
25th Feb 20227:00 amRNSDirectorate Change
24th Feb 20222:01 pmRNSPrice Monitoring Extension
8th Feb 20227:00 amRNSAward of Share Options
7th Feb 202211:01 amRNSPrice Monitoring Extension
20th Jan 20227:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSFirst Stereax Manufacturing Facility Opened
23rd Nov 20215:11 pmRNSHolding(s) in Company
19th Nov 20217:00 amRNSTrading Update & Notice of Half-year Results
10th Nov 20217:00 amRNSCapital Markets Day
22nd Sep 20213:30 pmRNSResult of AGM and Award of Bonus Share Options
10th Sep 20217:00 amRNSCommencement of trading on OTCQX Best Market in US
7th Sep 20217:00 amRNSSenior Appointments and Change of Director
24th Aug 20217:00 amRNSStereax Manufacturing Update
20th Aug 20217:00 amRNSNotice of AGM & Posting of Annual Report
5th Aug 20219:16 amRNSExercise of Options and Total Voting Rights
30th Jul 20214:32 pmRNSHolding(s) in Company
30th Jul 20219:54 amRNSDirector/PDMR Shareholding
29th Jul 20219:00 amRNSExercise of Options and Total Voting Rights
28th Jul 20211:14 pmRNSResults of GM, Open Offer and Total Voting Rights
12th Jul 202112:30 pmRNSPosting of Circular
9th Jul 20214:07 pmRNSResult of Placing and Retail Offer
9th Jul 20217:01 amRNSRetail Offer
9th Jul 20217:00 amRNSProposed Placing, Open Offer and Retail Offer
6th Jul 20217:00 amRNSFinal Results
5th Jul 202111:05 amRNSSecond Price Monitoring Extn
5th Jul 202111:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.